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Osteoblasts are specialized cells of mesenchy-
mal origin that synthesize the extracellular ma-
trix proteins required for mineralization of the 
embryonic skeleton (Erlebacher et al., 1995; 
Karsenty and Wagner, 2002). The high synthetic 
capacity of the osteoblast is also essential for 
maintaining bone mass during postnatal remod-
eling (Harada and Rodan, 2003). As bone accrues 
damage as the result of physiological exposure 
to mechanical stress, multinucleated giant cells 
termed osteoclasts localize at these sites and resorb 
the existing bone through an acidic and enzy-
matic process (Boyle et al., 2003). Osteoblasts 
are then recruited to sites of resorption where 
they secrete both collagenous and noncollage-
nous proteins that form the extracellular matrix 
that will give rise to newly mineralized bone 
(Martin et al., 2009). Functional dysregulation of 
osteoblasts during this remodeling process can af-
fect bone density and contributes to the patho-
genesis of skeletal disorders, such as osteoporosis, 
the most common skeletal disease worldwide 
(Zaidi, 2007). Thus, numerous regulatory path-
ways that control osteoblast differentiation and 
function exist to ensure that skeletal formation 
and remodeling proceed unperturbed.
Several regulatory mechanisms influencing 
osteoblast differentiation center on controlling 
the activity of the transcription factor Runx2 
(Lian et al., 2006). The expression of Runx2 in 
mesenchymal precursors is essential for their com-
mitment to the osteoblast lineage as demonstrated 
by the lack of both mature osteoblasts and a 
mineralized skeleton in Runx2/ mice (Komori 
et al., 1997; Mundlos et al., 1997; Otto et al., 
1997). Although the presence of a single copy of 
Runx2 is sufficient for mineralization to occur 
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Osteoblasts are responsible for the formation and mineralization of the skeleton. To iden-
tify novel regulators of osteoblast differentiation, we conducted an unbiased forward 
genetic screen using a lentiviral-based shRNA library. This functional genomics analysis led 
to the identification of the microtubule-associated protein DCAMKL1 (Doublecortin-like 
and CAM kinase–like 1) as a novel regulator of osteogenesis. Mice with a targeted disrup-
tion of Dcamkl1 displayed elevated bone mass secondary to increased bone formation by 
osteoblasts. Molecular experiments demonstrated that DCAMKL1 represses osteoblast 
activation by antagonizing Runx2, the master transcription factor in osteoblasts. Key 
elements of the cleidocranial dysplasia phenotype observed in Runx2+/ mice are reversed 
by the introduction of a Dcamkl1-null allele. Our results establish a genetic linkage between 
these two proteins in vivo and demonstrate that DCAMKL1 is a physiologically relevant 
regulator of anabolic bone formation.
© 2013 Zou et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it   
is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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differentiation through antagonism of Runx2 transcriptional 
activity. Analysis of Dcamkl1/Runx2 compound mutant mice 
revealed partial rescue of the clavicular hypoplasia, runting, and 
calvarial hypomineralization seen in Runx2 haploinsufficiency. 
These results provide genetic evidence that DCAMKL1 is an 
important novel regulator of Runx2, the master transcription 
factor for the osteoblast lineage.
RESULTS
A functional genomics approach to identify  
novel regulators of osteoblast differentiation
To identify unique genes that dictate the differentiation of mes-
enchymal stem cells (MSCs) into the osteoblast lineage, we ini-
tiated an unbiased screen that used a lentiviral-based shRNA 
library that targeted 1,500 different human kinases, phospha-
tases, and receptors with each gene in the library being covered 
by four to five separate shRNAs (http://www.broadinstitute 
.org/rnai/trc/lib; Moffat et al., 2006). This screen was con-
ducted in primary human MSCs that under the appropriate 
culture conditions can be reproducibly differentiated along 
the osteoblast lineage. As the human MSCs differentiate into 
osteoblasts, they up-regulate expression of the characteristic 
osteoblast marker alkaline phosphatase (Alp), which can be 
quantified via a simple colorimetric assay (Fig. 1 A). We used 
this characteristic of hMSCs to analyze the capability of the 
various shRNAs to alter differentiation into the osteoblast lin-
eage. As proof of principle that hMSC lineage commitment 
can be altered, we demonstrated that transduction of these 
cells with Runx2-specific shRNAs resulted in reduced osteo-
genesis, as shown by staining with Fast blue (Fig. 1 B). For the 
large-scale screen, Alp levels of lentivirus-infected MSCs were 
quantified after a 7-d culture period and were normalized to 
cell number with Alamar blue (Fig. 1 C). An Alp index (API) 
is assigned to each shRNA sample, and a list of candidates 
were identified in the screen based on the API of known genes 
that regulate MSC differentiation (see Materials and meth-
ods). Our screen and subsequent analysis demonstrated robust 
induction of Alp levels by shRNA directed against Dcamkl1, a 
member of the doublecortin family of microtubule-associated 
proteins (Omori et al., 1998; Burgess et al., 1999; Matsumoto 
et al., 1999; Sossey-Alaoui and Srivastava, 1999). We next asked 
whether reduction of DCAMKL1 protein levels by individual 
shRNAs correlated with osteoblast phenotype. As shown in 
Fig. 1 D, those hairpins that augmented Alp levels also reduced 
DCAMKL1 protein levels, as measured by Western blot analysis. 
More importantly, Dcamkl1-targeted shRNAs also induced   
elevated levels of mineral deposition as determined by von Kossa 
staining (Fig. 1 E). Collectively, these data demonstrate that 
knockdown of Dcamkl1 by shRNA hairpins can augment 
the differentiation of osteoblasts from undifferentiated human 
mesenchymal precursors in vitro.
DCAMKL1 regulates mouse osteoblast differentiation in vitro
To further explore the function of DCAMKL1 in osteoblas-
togenesis, we sought to establish whether this protein func-
tions in the mouse skeletal system. In situ hybridization of 
in vivo, Runx2+/ mice still exhibit delayed closure of the 
fontanelles and clavicular hypoplasia (Otto et al., 1997). The 
skeletal phenotype of Runx2+/ mice resembles the cleido-
cranial dysplasia phenotype arising from Runx2 haploinsuffi-
ciency in humans (Mundlos et al., 1997). The presence of these 
skeletal pathologies in both humans and mice underscores the 
importance of precise regulation of Runx2 levels and activity 
during osteogenesis.
Although a significant number of molecules, like Runx2, 
have been described to regulate osteoblast biology, the com-
plex temporal signaling networks that govern this process sug-
gest that many regulators of osteogenesis remain to be identified. 
Historically, molecules critical for osteoblast differentiation 
and function have been identified through single gene muta-
tions in humans and mice. Although this approach results in 
the identification of genes that are biologically relevant to the 
skeletal system, it is limited by the rate at which new genes 
are identified. Using a high-throughput forward genetic ap-
proach could accelerate the identification of additional mole-
cules and signaling pathways that regulate osteoblast biology. 
Unbiased functional genomics approaches using RNAi-based 
loss-of-function screens have been successful in identifying 
key molecules that regulate several physiological and patho-
logical processes (Moffat et al., 2006; Vasudevan et al., 2009; 
Kim et al., 2010). We therefore used arrayed libraries of 
lentiviral-based shRNAs to assess individual gene function 
during osteoblast differentiation in vitro.
DCAMKL1 (Doublecortin-like and CAM kinase–like 1) 
is a serine-threonine kinase of the CAMK family, showing 
homology to Doublecortin (DCX), which is mutated in   
X-linked lissencephaly (Omori et al., 1998; Burgess et al., 1999; 
Matsumoto et al., 1999; Sossey-Alaoui and Srivastava, 1999). 
An evolutionarily conserved Doublecortin (DC) domain that 
is able to bind to tubulin and enhance microtubule polymer-
ization exists in the N terminus of DCAMKL1 and DCX. 
Both DCAMKL1 and DCX are highly expressed in the devel-
oping brain and may function together to regulate microtu-
bules involved in neuronal migration. Dcamkl1-deficient mice 
are viable and fertile and display modest neural abnormalities 
(Deuel et al., 2006; Koizumi et al., 2006), suggesting that 
Doublecortin may provide partial functional compensation. 
Subsequent studies have demonstrated that DCAMKL1 exhibits 
variable expression patterns in embryonic and adult tissues out-
side of the central nervous system, suggesting that this protein 
may control additional physiological processes (May et al., 2008; 
Gerbe et al., 2009; Itzkovitz et al., 2012).
In this study, we describe a previously unknown role for 
DCAMKL1 within the skeletal system to regulate osteoblast 
functions and bone formation. We identified DCAMKL1 
through a functional genomics approach that used RNAi-
based loss-of-function screens to assess individual gene function 
during osteoblast differentiation in vitro. Mice lacking Dcamkl1 
exhibit an increase in osteoblast numbers, elevated bone mass, 
and increased rates of bone formation, which confirm that 
DCAMKL1 is a negative regulator of anabolic bone formation. 
This occurs via the ability of DCAMKL1 to control osteoblast JEM Vol. 210, No. 9 
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cell types that control bone formation and that differentiation 
and function of osteoblasts in vitro are sensitive to the endog-
enous levels of DCAMKL1.
Dcamkl1/ mice exhibit elevations  
in bone mass and bone anabolism
Mice deficient in Dcamkl1 have previously been generated and 
described to be viable and fertile (Deuel et al., 2006; Koizumi 
et al., 2006). To examine the effect of Dcamkl1 on skeleton de-
velopment, we first analyzed the growth plate of the Dcamkl1/ 
mice by hematoxylin and eosin (H&E) staining, revealing that 
Dcamkl1/ mice have a well-organized growth plate and that 
the growth plate architecture of these mice is indistinguish-
able from that of WT controls (Fig. 3 A). To further determine 
the in vivo effects of Dcamkl1 expression within the skeletal 
system, we used quantitative computed tomography (µ-QCT) to 
determine whether differences can be observed in skeletal el-
ements isolated from Dcamkl1/ mice when compared with 
skeletal elements from WT control mice. As shown in Fig. 3 
(B–F), the distal femurs of Dcamkl1/ mice exhibited in-
creases in trabecular bone volume (BV/TV), trabecular number 
embryonic day (E) 16.5 embryos revealed expression of Dcamkl1 
at several locations throughout the developing skeleton, 
including the vertebrae, ribs, and limbs (Fig. 2 A). We further 
explored whether Dcamkl1 was expressed in primary osteo-
blasts harvested from the calvarium of neonatal mice and com-
pared its expression in osteoblasts with that in other cellular 
populations within the skeleton. As shown in Fig. 2 B, Dcamkl1 
mRNA can be detected in whole bone, primary osteoblasts   
and to a much lesser extent in primary osteoclasts. Expres-
sion of Dcx, another member of the doublecortin family 
of microtubule-associated proteins, is restricted to the brain 
(Fig. 2 B). We also observed that DCAMKL1 protein levels are 
elevated during the course of osteoblast differentiation in vitro 
(Fig. 2 C). Similar to the results in human MSCs, shRNA-
mediated reductions in endogenous DCAMKL1 protein lev-
els augmented osteogenesis in mouse osteoblasts (Fig. 2, D–F). 
When compared with control shRNA targeting GFP, intro-
duction of shRNA specific for Dcamkl1 into primary osteoblast 
cultures increased osteoblast-specific gene expression and in-
creased formation of mineralized matrix (Fig. 2, D–F). These 
results further demonstrate that Dcamkl1 is expressed within 
Figure 1.  Identification of DCAMKL1 in a lentiviral-based shRNA screen in hMSCs. (A) Alp in MSCs cultured in basal maintenance media 
(MSCGM) or in osteoblast differentiation media (OBD). Results are presented as the mean ± SD of triplicates of cells cultured in 96-well plates and are 
representative of two independent experiments. (B) Fast blue staining for Alp-positive cells after infection with lentivirus expressing Runx2-specific 
shRNAs 1–3. The data are representative of two independent experiments. (C) XY scatter plot of Alp (y axis) and cell number (x axis) depicting the effects 
of individual shRNA on hMSC differentiation. (D) Analysis of DCAMKL1 protein expression in hMSCs after infection with control shRNA targeting GFP or 
Dcamkl1-specific shRNAs. (E) von Kossa staining of hMSCs infected with lentivirus expressing control or Dcamkl1 shRNAs cultured in osteoblast differen-
tiation media for 21 d. The data are representative of two independent experiments. Bars: (B) 20 µm; (E) 4 mm.1796 DCAMKL1 is a repressor of osteogenesis | Zou et al.
To assess whether the increase in osteoblasts is related to ex-
pansion of a pool of osteoprogenitor cells, flow cytometric 
analysis of this population was performed. Recently, a popula-
tion of osteoprogenitor cells with surface markers CD45 
Tie2v+CD105+Thy1.2 (CD105+Thy1) was isolated from 
bone marrow cells (Chan et al., 2009). This population of cells 
can produce bone through endochondral ossification. To assess 
whether there are more osteoprogenitors in the bone marrow 
of Dcamkl1/ mice, bone cells were isolated from WT and 
Dcamkl1/ mice and analyzed using flow cytometry. Dcamkl1 
knockout embryos showed similar numbers of CD105+Thy1 
osteoprogenitor cells when compared with littermate controls 
(Tb.N), trabecular thickness (Tb.Th), and cortical thickness 
(C.Th) when compared with the femurs of WT control mice. 
Given our previous findings that Dcamkl1 can regulate osteo-
blast differentiation and function in vitro, we used histomor-
phometric analysis of WT and Dcamkl1/ mice to evaluate 
static and dynamic parameters of bone formation and resorp-
tion (Fig. 3 G and Table 1). Consistent with our µ-QCT data, 
histomorphometric analysis also demonstrated that Dcamkl1/  
mice  displayed  significant  increases  in  both  bone  volume 
(BV/TV) and trabecular thickness (Tb.Th; Fig. 3 G and Table 1). 
Also, a marked elevation in the number of osteoblasts was 
observed in tibias isolated from Dcamkl1/ mice (Table 1). 
Figure 2.  Augmented osteoblast differentiation after silencing of Dcamkl1. (A) Analysis of Dcamkl1 expression in E16.5 embryos via in situ hybridization. 
(B) RT-PCR analysis of Dcamkl1, Dcx, and -actin transcript levels in brain, whole bone, osteoblasts (OB), and osteoclasts (OC). The data are representative of three 
mice per group and two independent experiments. (C) Analysis of DCAMKL1 protein levels by Western blot over the course of osteoblast differentiation. The data 
are representative of two independent experiments. (D) Western blot analysis of DCAMKL1 protein levels in osteoblasts that were infected with lentivirus express-
ing control shRNA or two separate Dcamkl1-specific shRNAs. (E) qRT-PCR analysis of osteoblast-specific genes in cells infected with control or Dcamkl1-specific 
shRNAs. (F) Osteoblasts infected with control or Dcamkl1-specific shRNAs were cultured for 21 d, and von Kossa staining for mineralization and Fast blue staining 
for Alp activity were performed. (A, E, and F) The data are representative of three independent experiments. Bars: (A) 100 µm; (F) 20 µm.JEM Vol. 210, No. 9 
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Figure 3.  Elevated bone mass present in mice lacking Dcamkl1. (A) H&E staining of distal femur of 4-wk-old WT and Dcamkl1/ mice showing the 
growth plate architecture of these mice. The data are representative of two independent experiments. (B) 3-D µ-QCT image of distal femurs isolated from 
9-wk-old male Dcamkl1/ and WT control mice. (C–F) Analysis of µ-QCT femur images from 9-wk-old male WT and Dcamkl1/ mice for bone volume per 
tissue volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and cortical thickness (C.Th). Results are presented as the mean ± SD of six mice 
per group. (G) von Kossa staining and histomorphometry analysis of proximal tibia from 9-wk-old male Dcamkl1/ and control mice. Results are representa-
tive of five mice per group. (H) Representative FACS profiles on pregated, CD45Ter119 lineage cells harvested from long bone WT and Dcamkl1 knockout 
embryos. Percentages represent the percentage of cells within that quadrant. Values are mean ± SD of biological replicates. (I) Dual calcein labeling of tibial 
bone from WT and Dcamkl1/ mice was visualized by fluorescent microscopy. Results are representative of five mice per group. (J) von Kossa staining of WT 
and Dcamkl1/ osteoblast cultures at day 16. (K–O) Analysis of Tnalp (K), Bsp (L), Ocn (M), and Sost (O) via qPCR in WT and Dcamkl1/ osteoblast cultures. 
Results are presented as the mean ± SD of triplicates of cells pooled from three mice per group and are representative of two independent experiments.  
Statistical analysis was performed using an unpaired Student’s t test: *, P < 0.05. Bars: (A) 100 µm; (B and G) 300 µm; (I) 10 µm; (J) 20 µm.
(Fig. 3 H and Fig. S1). Thus, by comparing the number of os-
teoprogenitors with the results of histomorphometry analysis, 
we conclude that DCAMKL1 likely functions during osteo-
blast differentiation, after commitment to the osteoblast lineage. 
Thus, increased numbers of osteoblasts and enhanced bone 
formation in Dcamkl1/ mice reflect accelerated osteoblast dif-
ferentiation, which is consistent with the results of our in vitro 
knockdown experiments (Fig. 1, D and E; and Fig. 2, D–F).1798 DCAMKL1 is a repressor of osteogenesis | Zou et al.
Dcamkl1/ mice showed similar numbers of TRAP-positive 
cells (Fig. 4, A and B). Further confirming these in vivo find-
ings, bone marrow harvested from Dcamkl1/ mice and cul-
tured in the presence of osteoclast inducers RANKL (receptor 
activator of NF-B ligand) and M-CSF resulted in the forma-
tion of a similar number of multinucleated TRAP-positive 
osteoclasts when compared with bone marrow from WT mice 
(Fig. 4 C). Further analysis of these cultures via quantitative 
PCR (qPCR) revealed that the osteoclast-specific markers 
cathepsin K, 3-integrin, and calcitonin receptor were induced 
to similar levels in WT and Dcamkl1/ cultures when these 
cells were cultured under conditions that promote osteoclas-
togenesis (Fig. 4, D–F). Collectively, these results suggest that 
the elevated bone mass observed in Dcamkl1/ mice is attrib-
uted to increased bone formation by osteoblasts as opposed to 
impaired bone resorption by osteoclasts.
DCAMKL1 regulates the activity of Runx2 in osteoblasts
We next sought to elucidate the mechanism underlying con-
trol of osteoblast differentiation by DCAMKL1. Runx2 is a 
transcription factor essential for osteoblast differentiation and 
functions. We therefore reasoned that DCAMKL1 might exert 
its inhibitory influence on osteoblast biology through antago-
nism of Runx2. To address this question, we asked whether 
overexpression of DCAMKL1 could alter the ability of Runx2 
to activate transcription from the well-characterized OSE2 
luciferase reporter construct that contains multimerized Runx2-
binding sites (Ducy et al., 1997). As shown in Fig. 5 A, ec-
topic expression of DCAMKL1 did indeed inhibit Runx2 
Additionally,  bone  formation  rates  were  elevated  in 
Dcamkl1/ mice compared with control mice. This was caused 
by an increase in both mineral apposition rate and mineraliz-
ing surface as determined by dual-calcein labeling (Fig. 3 I 
and Table 1). To further verify that the increased bone mass 
observed in Dcamkl1/ mice is the effect of augmented os-
teoblast activity, WT and Dcamkl1/ bone marrow stromal 
cells were differentiated into osteoblasts. The primary osteo-
blast cultures from Dcamkl1/ mice demonstrated an increased 
level of mineralized matrix production (Fig. 3 J). Consistent 
with the enhanced mineralized matrix formation, expression 
of characteristic osteoblast markers including tissue-nonspecific 
Alp (Tnalp), bone sialoprotein (Bsp), and osteocalcin (Ocn) 
were increased in Dcamkl1/ osteoblasts when compared 
with WT osteoblasts (Fig. 3, K–M).The increased bone mass 
observed in the Dcamkl1/ mice may be caused by alteration 
of Wnt–LRP5 pathways. We also examined the expression 
of the secreted WNT antagonist SOST and did not find ob-
vious difference (Fig. 3 O). These data confirm our previous 
in vitro observation that Dcamkl1-specfic shRNAs can aug-
ment osteoblast differentiation and establish that the increased 
bone mass observed in the Dcamkl1/ mice arises from ele-
vated osteoblast activity.
The increased bone mass present in the long bones of 
Dcamkl1/ mice could also arise through impaired osteoclast 
differentiation and/or function. To address this, we analyzed 
tibias from 4-wk-old WT and Dcamkl1/ mice for the pres-
ence of tartrate-resistant acid phosphatase (TRAP)–positive 
osteoclasts. In comparison with age-matched WT controls, 
Table 1.  Histomorphometry analysis of Dcamkl1/ mice
Parameter WT (n = 6) Dcamkl1/ (n ≥ 5) P-value
BV/TV (%) 6.13 ± 0.74 10.39 ± 1.32a 0.018
Tb.Th (µm) 28.22 ± 1.01 34.23 ± 1.42b 0.006
Tb.N (/mm) 2.18 ± 0.25 3.01 ± 0.29 0.055
Tb.Sp (µm) 464 ± 56 316 ± 39 0.055
MS/BS (%) 36.68 ± 1.80 42.16 ± 1.38a 0.045
MAR (µm/d) 1.81 ± 0.05 2.16 ± 0.14a 0.033
BFR/BS (µm3/µm2/yr) 242 ± 13 331 ± 20b 0.004
BFR/BV (%/yr) 1,711 ± 36 2,016 ± 142a 0.048
BFR/TV (%/yr) 105 ± 12 184 ± 12b 0.001
Ob.S/BS (%) 10.19 ± 2.14 15.55 ± 1.27 0.057
N.Ob/T.Ar (/mm2) 33.96 ± 5.19 81.52 ± 14.18a 0.010
N.Ob/BS (/mm) 8.68 ± 1.62 13.26 ± 1.11a 0.042
OS/BS (%) 5.56 ± 1.01 5.88 ± 0.94 0.824
O.Th (µm) 2.49 ± 0.33 2.40 ± 0.29 0.854
Oc.S/BS (%) 0.84 ± 0.21 0.57 ± 0.14 0.303
N.Oc/T.Ar (/mm2) 1.74 ± 0.59 1.54 ± 0.38 0.783
N.Oc/BS (/mm) 0.37 ± 0.08 0.24 ± 0.06 0.205
Tb.Sp, trabecular separation; N.Ob/T.Ar, osteoblast number/tissue area ratio; N.Ob/BS, osteoblast number/bone surface; N.Oc/T.Ar, osteoclast number/tissue area ratio; N.Oc/BS, 
osteoclast number/bone surface. 9-wk-old male Dcamkl1/ mice and WT control mice were injected with calcein. 5 d later, mice were injected with calcein again. Mice were 
sacrificed 3 d after the second injection, and tibias were processed for quantitative histomorphometry. Histomorphometric analysis at proximal tibiae revealed that 
Dcamkl1/ mice had significantly higher cancellous bone volume and thicker trabeculae than WT controls.
aP < 0.05 compared with WT, unpaired Student’s t test.
bP < 0.01 compared with WT, unpaired Student’s t test.JEM Vol. 210, No. 9 
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the kinase domain but lacking the doublecortin domains   
was unable to block transactivation by Runx2 (Fig. 5 E). A   
full-length DCAMKL1 mutant harboring a point mutation 
that renders the kinase region nonfunctional but retains its   
microtubule-polymerizing  activity  was  also  capable  of  in-
hibiting Runx2 activity in vitro (Fig. 5 F), indicating that 
DCAMKL1 represses Runx2 through its ability to promote 
microtubule polymerization, not its kinase activity.
We next questioned whether DCAMKL1 can promote 
microtubule polymerization in osteoblasts. To address this, 
osteoblasts were transfected with a construct expressing EGFP 
or EGFP-tagged DCAMKL1 constructs. Osteoblasts transfected 
with EGFP-DCAMKL1 formed numerous dendrite-like pro-
cesses that were rich in DCAMKL1 expression (Fig. 5 H). 
Staining the cultured cells with anti-tubulin antibody revealed 
that these dendrite-like processes containing DCAMKL1 were 
also rich in tubulin (Fig. 5 H). Similar to what was observed 
with full-length DCAMKL1, transfection of the EGFP-DCL 
mutant protein that only expresses the doublecortin domain 
also resulted in the formation of tubulin-rich, dendrite-like 
processes (Fig. 5 I). As a control, transfection of EGFP or 
EGFP-CPG16 did not facilitate the formation of tubulin-rich, 
dendrite-like processes (Fig. 5, G and J). These data demon-
strate that the doublecortin domains of DCAMKL1 are required 
for both microtubule polymerization and for inhibition of 
Runx2. Given that a previous study has demonstrated that 
the stabilization of microtubules results in the cytoplasmic 
transactivation of this reporter gene. In contrast, DCAMKL1 
had no effect on the transcriptional activation of ATF4, an-
other key transcription factor in osteoblast biology (Fig. 5 B). 
Interestingly, we were unable to detect an association between 
DCAMKL1 and Runx2 in coimmunoprecipitation experi-
ments (Fig. 5 C), suggesting that the repression of Runx2 func-
tion by DCAMKL1 occurs in the absence of a direct interaction 
between these two proteins.
To gain further insight into how DCAMKL1 controls 
Runx2 activity, we sought to identify those structural domains 
of DCAMKL1 that are required to repress Runx2 activity. 
DCAMKL1 contains a pair of unique doublecortin domains 
in the N terminus that facilitate its association with micro-
tubules and promote their polymerization (Fig. 5 D; Burgess 
and Reiner, 2000; Lin et al., 2000). DCAMKL1 also contains 
a functional Ca2+/calmodulin-dependent (CAM)–like kinase 
domain in its C terminus, although physiologically relevant 
substrates for this kinase have yet to be described (Fig. 5 D; 
Lin et al., 2000; Burgess and Reiner, 2002; Shang et al., 2003). 
Using a series of truncated mutant proteins of DCAMKL1 in 
the same luciferase reporter system described above, we found 
that the inhibitory function of DCAMKL1 requires the presence 
of the microtubule-associating doublecortin domains (Fig. 5, 
E and F). As shown in Fig. 5 E, expression of a C-terminal 
truncated DCAMKL1 mutant containing the doublecortin 
domains (DCL) retained its ability to repress Runx2 transac-
tivation. In contrast, a truncated DCAMKL1 mutant containing 
Figure 4.  Normal osteoclast differentiation in Dcamkl1/ mice. (A) Histological analysis of TRAP-positive osteoclast populations in the tibia of  
4-wk-old male WT and Dcamkl1/ mice. The data are representative of two independent experiments. (B) Histomorphometry analysis of osteoclast sur-
face per tissue area (N.Oc/T.Ar) in the tibia of 9-wk-old male WT control and Dcamkl1/ mice. Results are presented as the mean ± SD of six mice per 
group. (C) In vitro differentiation of osteoclast precursors from bone marrow cells of WT and Dcamkl1/ mice in the presence M-CSF + RANKL. Cultures 
were then assayed for the presence of TRAP-positive mature osteoclasts. The data are representative of two independent experiments. Bars: (A) 100 µm;  
(C) 60 µm. (D–F) qPCR analysis of WT and Dcamkl1/ osteoclast cultures for the expression of cathepsin K (D), 3-integrin (E), and calcitonin receptor 
(F). Results are presented as the mean ± SD of triplicates of cells pooled from three mice per group and are representative of two independent experiments.1800 DCAMKL1 is a repressor of osteogenesis | Zou et al.
mutant, or a control GFP expression vector were transfected 
into cells expressing myc epitope–tagged Runx2. Analysis of 
cells transfected with the control GFP expression vector re-
vealed that Runx2 localization was predominantly nuclear 
sequestration of Runx2 (Pockwinse et al., 2006), we ques-
tioned whether DCAMKL1 may repress Runx2 transcrip-
tional activity through sequestering Runx2 in the cytoplasm. 
To assess this, GFP-tagged DCAMKL1, GFP-tagged DCL 
Figure 5.  DCAMKL1 regulates microtubule polymerization and Runx2 activity in osteoblast cultures. (A and B) Measurement of Runx2-responsive 
OSE2 luciferase activity (A) and ATF4-responsive OSE1 luciferase activity (B) in C3H10T1/2 cells with or without DCAMKL1 expression. Results are from lysates 
harvested from cells 48 h after transfection and were normalized to the expression of the pRL-TK plasmid. Results are presented as the mean ± SD of tripli-
cates of cells and are representative of two independent experiments. (C) The interaction between Runx2 and DCAMKL1 was analyzed by coimmunoprecipita-
tion experiments, which were conducted in 293T cells transfected with Myc-Runx2 and EGFP-Dcamkl1 expression constructs. Runx2 was immunoprecipitated 
from cell lysates with anti-Myc antibody, followed by Western blot analysis with anti-GFP antibody. IB, immunoblot; IP, immunoprecipitation. (D) Linear sche-
matic of the various Dcamkl1 mutants used in these experiments. MBDs, microtubule-binding domains. (E and F) Measurement of Runx2-responsive OSE2 
luciferase activity in C3H10T1/2 cells, which were transfected with the p6xOSE2-Luc reporter plasmids and combinations of Runx2 and different DCAMKL1 
expression constructs. Results are presented as the mean ± SD of triplicates of cells and are representative of two independent experiments. (G–J) Staining of 
cells transfected with constructs expressing EGFP (G), EGFP-DCAMKL1 (H), EGFP-DCL (I), or EGFP-CPG16 (J) with anti-tubulin antibody and Hoechst to visual-
ize microtubules and nuclei, respectively. (K–M) C3H10T1/2 cells were cotransfected with Myc-Runx2 and constructs expressing EGFP (K) and EGFP-Dcamkl1 
(L) or EGF-Dcl (M) and were stained with an anti-Myc antibody. Results are representative of two independent experiments. Bars, 10 µm.JEM Vol. 210, No. 9 
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WT and Dcamkl1/ mice. In contrast, mice with deletions 
of Dcamkl1 and heterozygosity for Runx2 were similar in 
size to WT mice (Fig. 7, A and B). Furthermore, the hypo-
plasia of the clavicle in Runx2+/ mice was partially normal-
ized in the Dcamkl1/Runx2+/ compound mutant mice 
(Fig. 7, C and D). Dcamkl1/Runx2+/ compound mutant 
mice also exhibited significant normalization of the calvar-
ial hypomineralization phenotype of Runx2+/ mice (Fig. 7 E). 
Collectively, these data indicate a genetic interaction between 
Dcamkl1 and Runx2 and provide in vivo verification that 
DCAMKL1 is a negative regulator of Runx2 within the skele-
tal system.
DISCUSSION
Although the transcriptional control of anabolic bone formation 
is an area of active investigation, much remains to be learned 
about the genetic programs that modulate the function of key 
transcription factors in osteoblast differentiation and activation. 
Here we used a functional genomics approach to identify novel 
regulators of osteogenesis. This forward genetic screen yielded 
the microtubule-associated protein DCAMKL1 as a previously 
unrecognized negative regulator of osteoblast differentiation. 
In vitro and in vivo analyses revealed that DCAMKL1 repressed 
osteoblast activation by antagonizing Runx2, the master tran-
scription factor in osteoblasts. Introduction of a homozygous 
Dcamkl1-null allele into Runx2 heterozygous mice reversed as-
pects of the cleidocranial dysplasia phenotype of these mutant 
animals. Our results establish a genetic interaction between 
Dcamkl1 and Runx2 in vivo and demonstrate that DCAMKL1 
is a physiologically relevant regulator of Runx2-mediated 
anabolic bone formation. Our study validates the usefulness 
of a functional genomics approach to discover novel regula-
tors of osteogenesis.
Our findings demonstrate that DCAMKL1 regulates bio-
logical processes outside of the central nervous system. Similar 
to the function of DCAMKL1 in the central nervous system, 
this protein can also augment microtubule polymerization in 
osteoblasts. The inhibitory effects of DCAMKL1 on osteoblast 
differentiation may be explained by its ability to promote mi-
crotubule polymerization, a suggestion supported by previous 
reports demonstrating that treatment of osteoblast cultures with 
known inhibitors of microtubule assembly can enhance osteo-
blast differentiation in vitro (Zhao et al., 2009). Furthermore, 
it has been demonstrated that treatment of mice with these 
microtubule assembly inhibitors increased bone mass in vivo 
through augmentation of bone formation rates, mirroring what 
is observed in Dcamkl1/ mice (Zhao et al., 2009). In addi-
tion to DCAMKL1, other proteins that associate with micro-
tubules are also expressed in osteoblasts (Chiellini et al., 2008). 
The transcription of Stathmin-like 2 (Stmn2), a member of the 
stathmin family of cytosolic phosphoproteins, is up-regulated 
in hMSCs during osteoblast differentiation. However, in con-
trast to DCAMKL1, stathmins are a class of microtubule acces-
sory proteins that inhibit microtubule polymerization (Curmi 
et al., 1999). Osteoblast differentiation and function may there-
fore depend on a precise regulation of multiple proteins that 
and the subcellular distribution of Runx2 was not perturbed 
by GFP (Fig. 5 K). Similar to the observation described above, 
ectopic expression of the full-length DCAMKL1 or the DCL 
mutant promoted the formation of dendrite-like processes 
(Fig. 5, L and M). However, Runx2 was still retained in the 
nucleus of those cells expressing full-length DCAMKL1 or 
the DCL mutant (Fig. 5, L and M).
Multiple studies have documented that the regulation of 
Runx2 transcriptional activity is influenced through posttrans-
lational modifications of specific residues within this protein 
(Bae and Lee, 2006; Jonason et al., 2009). We therefore asked 
whether DCAMKL1 can alter the phosphorylation pattern of 
Runx2. For this, we purified Runx2 from 293T cells that either 
coexpressed DCAMKL1, the DCL mutant of DCAMKL1, 
or cells treated with the well-characterized microtubule-
stabilizing agent taxol (Fig. 6 A). Mass spectroscopy analysis 
of the purified Runx2 protein revealed that the presence of 
DCAMKL1 resulted in the phosphorylation of serine residue 
125 (Ser125; Fig. 6, B and C). Interestingly, Ser125 phos-
phorylation is also detectable on Runx2 when it is purified 
from taxol-treated cells and from cells cotransfected with the 
DCL mutant of Dcamkl1 but is not detectable in control cells 
(Fig. 6 B). To further test whether the inhibition of Runx2 
by DCAMKL1 is through the phosphorylation of Runx2 at 
Ser125, we constructed a mutant Runx2 in which Ser125 
was mutated to glutamic acid to mimic phosphorylation of 
Ser125. Strikingly, Runx2 S125E mutation substantially de-
creased Runx2 activity. More importantly, DCAMKL1 could 
not further decrease the activity of the Runx2 S125E mutant 
(Fig. 6 D). A previous study has established that phosphory-
lation of Ser125 in Runx2 renders Runx2 transcriptionally 
inert (Phillips et al., 2006). Considering that the microtubule 
stabilizing agent Taxol could also induce Ser125 phosphory-
lation, our data support the conclusion that Runx2 inhibition 
by DCAMKL1 occurs through the induction of microtubule 
stabilization and the phosphorylation of Runx2 at this negative-
regulatory serine residue.
Generation and analysis of Dcamkl1/Runx2 compound 
mutant mice reveal a genetic interaction in vivo
Based on the in vitro findings described above, we asked whether 
DCAMKL1 is a bona fide regulator of Runx2 in vivo. Runx2 
haploinsufficiency in humans and mice results in the syndrome 
cleidocranial dysplasia, which is characterized by the delayed 
closure of the fontanelles and clavicular hypoplasia (Otto et al., 
1997). We postulated that if DCAMKL1 is indeed a negative 
regulator of Runx2 transcriptional activity, then deletion of 
Dcamkl1 in parallel with Runx2 haploinsufficiency in vivo should 
lead to amelioration of the skeletal patterning defects observed 
in Runx2+/ mice. To test this hypothesis, we analyzed skel-
etal preps generated from WT, Dcamkl1/, Runx2+/, and 
Dcamkl/Runx2+/ compound mutant mice that were stained 
with alizarin red and Alcian blue to visualize the various skel-
etal elements. As shown in Fig. 7 (A–E), Runx2+/ mice dis-
play the previously reported cleidocranial dysplasia–like skeletal 
abnormalities and are also slightly runted when compared with 1802 DCAMKL1 is a repressor of osteogenesis | Zou et al.
Figure 6.  DCAMKL1 regulates Runx2 activity, accompanied by Runx2 Ser125 phosphorylation. (A) Coomassie blue staining of purified Flag-
Runx2 protein, which is used for the determination of Runx2 phosphorylation sites by mass spectroscopy. 293T cells were cotransfected with Flag-
Runx2 and Dcamkl1 or DCL expression plasmids; after 48 h, Flag-Runx2 protein was purified from 293T cells using M2 beads from Sigma-Aldrich. For 
the Taxol treatment, the cells were treated with 0.1 µM Taxol for 16 h before harvesting the protein. (B) Schematic indicating the Runx2 phosphoryla-
tion sites identified by MS spec analysis. (C) Representative MS/MS spectra for Ser125 phosphorylated TDSPNFLCSVLPSHWR peptide. The mass differ-
ence between the peaks corresponds directly to the amino acid sequence. The predicated fragmentation patterns, which are indicated by b ions (blue) 
and y ions (red), are included to establish a sequence both forward (b ions) and backward (y ions). MS/MS spectra were searched using the SEQUEST 
algorithm allowing for phosphorylation of serine, threonine, and tyrosine residues. Each spectrum was matched with a q-value of <1%. (D) Effects of 
Dcamkl1 on WT Runx2 and the Runx2-S125E mutant were assessed by p6xOSE2-Luc reporter in C3H10T1/2 cells. Results are presented as the mean ± 
SD of triplicates of cells and are representative of two independent experiments.JEM Vol. 210, No. 9 
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control the dynamic nature of microtubule polymerization 
and depolymerization.
We further demonstrate that DCAMKL1 antagonizes the 
activity of Runx2 in a transient reporter assay. We found that 
the ability of DCAMKL1 to repress Runx2 transcriptional activ-
ity required the Doublecortin domains of DCAMKL1. The 
Doublecortin domains are required for the microtubule-
polymerizing activity of DCAMKL1, suggesting that Runx2 
activity may be sensitive to active polymerization of micro-
tubules. Coexpression of DCAMKL1 with Runx2 resulted in 
phosphorylation of Runx2 at Ser125. A previous study has 
demonstrated that phosphorylation of this serine residue in-
hibits Runx2 activity (Phillips et al., 2006). Mutation of the 
corresponding serine residue in human Runx2 has also been 
identified in a patient with cleidocranial dysplasia, suggesting 
that phosphorylation of this residue can influence Runx2 activ-
ity in vitro and in vivo (Wee et al., 2002). Although DCAMKL1 
contains a functional kinase domain, phosphorylation of Ser125 
on Runx2 was also observed in cells transfected with the DCL 
mutant, suggesting that the microtubule-stabilizing function 
of DCAMKL1 is necessary for its ability to induce phosphory-
lation of Runx2. Furthermore, phosphorylation of Runx2 at 
Ser125 could be promoted by taxol, a microtubule-stabilizing 
agent. Understanding how DCAMKL1-mediated microtubule 
polymerization promotes the phosphorylation of Runx2 is an 
area of active investigation. It has been established that micro-
tubules can facilitate signaling from the cell surface to the nu-
cleus through retrograde transport of kinases (Moises et al., 
2007). Therefore, stabilization of microtubules by DCAMKL1 
within osteoblasts may facilitate the localization of certain ki-
nases in the nucleus that promote Runx2 phosphorylation.
A previous study has demonstrated that DCAMKL1 reg-
ulates the transition from prometaphase to metaphase through 
a process that also requires its doublecortin domains (Shu et al., 
2006). DCAMKL1 may therefore alter osteoblast differentia-
tion through affecting cell cycle progression. Indeed, commit-
ment of MSCs to the osteoblast lineage requires exiting from 
the cell cycle, a process which is mediated by Runx2 (Pratap 
et al., 2003). Altering the DNA-binding and transcriptional 
activity of Runx2 at various stages of the cell cycle may dic-
tate the stage-specific expression of genes that are essential for 
driving osteoblast lineage commitment (Qiao et al., 2006). 
This oscillation of microtubule polymerization and depoly-
merization, mediated by various mitogen-activated proteins 
(MAPs) such as DCAMKL1 may coordinate cell cycle with 
Runx2 transcriptional activity.
Through the generation and analysis of Dcamkl1/Runx2 
compound mutant mice, we established that the cleidocranial 
dysplasia phenotype observed in Runx2+/ mice can be par-
tially reversed by deletion of Dcamkl1 and provided in vivo 
evidence that Dcamkl1 is a bona fide regulator of Runx2. In 
addition to regulating osteoblast lineage commitment, Runx2 
has also been reported to regulate chondrocyte maturation as 
well. To examine the effect of Dcamkl1 on chondrocyte de-
velopment, we analyzed the growth plate of the Dcamkl1/ 
mice by Safranin O staining and H&E staining (Fig. 3 A and 
Figure 7.  Dcamkl1 genetically interacts with Runx2. (A) Body weight 
analysis of neonatal WT, Runx2+/, Dcamkl1/, and Dcamkl1/Runx2+/ 
mice. Results are presented as the mean ± SD of at least six mice per group. 
(B, C, and E) Alizarin red– and Alcian blue–stained skeletal preps of P3 WT, 
Dcamkl1/, Runx2+/, and Dcamkl1/Runx2+/ mice demonstrates runt-
ing (B), clavicular hypoplasia (C), and delayed closure of fontanelles (E) in 
Runx2+/ mice. The red arrow in C indicates the presence of a short clavicle. 
Results are representative of at least four mice per group. Bars: (B) 600 µm; 
(C) 300 µm; (E) 500 µm. (D) The clavicle length of p3 WT, Dcamkl1/, 
Runx2+/, and Dcamkl1/Runx2+/ mice was quantified. Results are pre-
sented as the mean ± SD of at least eight mice per group. Statistical analy-
sis was performed using an unpaired Student’s t test: *, P < 0.001.1804 DCAMKL1 is a repressor of osteogenesis | Zou et al.
Immunohistochemistry and in situ hybridization. Mouse embryos and 
tissues were fixed in 4% paraformaldehyde (PFA) and embedded in paraffin. 
For in situ hybridization, a DIG labeling kit (Roche) was used to label digoxi-
genin (DIG) probes as per the manufacturer’s instructions. In brief, DIG-
labeled antisense probes were prepared with T7 RNA polymerase to detect   
Dcamkl1 mRNA expression. Probes for Dcamkl1 were amplified from pri-
mary mouse osteoblast cDNA using the following primers: Dcamkl1-5,   
5-AAGTCAGTACCAGCAAGTCTCC-3; and Dcamkl1-3-T7, 5-TTG-
TAATACGACTCACTATAGGGGCTGCAGATCAGTGTAGAGTTCG-3.  
Probes were purified by washing over an Ultrafree-MC filter column 
(EMD Millipore). Tissue sections were prewarmed at 55°C and deparaf-
finized and rehydrated by passage through xylene and 100, 95, and 70% 
ethanol. To quench endogenous peroxidase activity, sections were incu-
bated in 3% hydrogen peroxide for 15 min. Samples were then treated with 
10 µg/ml proteinase K for 15 min, 4% PFA for 5 min, and 0.25% acetic 
acid for 15 min before being dehydrated by passage through increasing con-
centrations of ethanol. Probe was added to the hybridization solution (50% 
formamide, 10 mM Tris-HCl, pH 7.5, 200 µg/ml tRNA, 1× Denhardt’s,   
10% dextran sulfate, 600 mM NaCl, 0.25% SDS, and 1 mM EDTA), and the 
solution was prewarmed to 85°C before incubation with the tissue sections   
overnight. After incubation, sections were washed with standard Na citrate 
buffer and treated with 10 µg/ml RNase A in TNE buffer (10 mM Tris-HCl, 
100 mM NaCl, and 1 mM EDTA). DIG-labeled probe was then detected by 
immunostaining with anti–DIG-POD and streptavidin–horseradish peroxi-
dase. The enzyme reaction was stopped by water, and the slides were counter-
stained in hematoxylin and dehydrated and mounted in xylene-based media.
Skeletal preparation and staining. Mice were skinned, eviscerated, and 
dehydrated in 95% EtOH overnight. The samples were then transferred into 
acetone for an additional 48-h incubation. Skeletal preparations were stained 
for 2 d using Alcian blue and alizarin red as described previously (McLeod, 
1980). After staining, the samples were washed three times for 30 min in 
95% EtOH. Soft tissue was then cleared in 1% KOH.
Micro-computed tomography (µCT) analysis. Femurs were isolated 
from 9-wk-old male WT and Dcamkl1/ mice and fixed in 70% EtOH. A 
region 0.28 mm proximal to the distal growth plate was scanned using a µCT 
35 system (Scanco Medical) with a spatial resolution of 7 µm. From these 
scans, a region of 2.1 mm in length of the distal metaphysis was selected for 
analysis. Images were reconstructed into three-dimensional (3-D) volumes 
with the region of interest being segmented using a fixed threshold. Unbiased, 
3-D microstructural properties of trabecular bone, including bone volume 
fraction (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), 
cortical thickness (C.Th), were then calculated for the trabecular region of 
the metaphysis of the distal femur using methods based on distance transfor-
mation of the binarized images (Hildebrand and Rüegsegger, 1997).
Bone histomorphometry. 9-wk-old male WT and Dcamkl1/ mice were 
intraperitoneally injected with 20 mg/kg calcein on days 8 and 3 before nec-
ropsy. Tibiae were removed, dehydrated in ethanol, infiltrated, and embedded 
without demineralization in methyl methacrylate. Undecalcified sections were 
cut at a thickness of 5 µm and mounted unstained for dynamic measurements. 
Consecutive sections were stained with toluidine blue to quantitate bone cell 
measurements. Histomorphometric analysis was performed using the Osteo-
Measure system (Osteometrics, Inc.), and the results were expressed according 
to standardized nomenclature (Parfitt et al., 1987). A sampling site with an area 
of 1.2 mm2 was established in the secondary spongiosa of the metaphysis. 
The dynamic measurements included mineral apposition rate (MAR), miner-
alizing surface (MS/BS), and bone formation rate expressed per bone sur-
face referent (BFR/BS), bone volume referent (BFR/BV), and tissue volume   
referent  (BFR/TV).  Osteoblast  surface  (Ob.S/BS)  and  osteoclast  surface 
(Oc.S/BS) were determined as trabecular surface covered by large basophilic 
cuboidal cells and multinucleated (two or more nuclei) cells, respectively. Os-
teoblast number (N.Ob) and osteoclast number (N.Oc) were counted and ex-
pressed per bone perimeter (B.Pm) and tissue area (T.Ar). Osteoid surface 
(OS/BS) and osteoid thickness (O.Th) were also measured.
not depicted), revealing that Dcamkl1/ mice have a well-
organized growth plate and that the growth plate architecture 
of these mice is indistinguishable from that of WT controls. 
The absence of a growth plate phenotype in the Dcamkl1-null 
mice may result from compensatory mechanisms that arise 
between DCAMKL1 and other microtubule-associated pro-
teins expressed in these tissues. Interestingly, another member 
of the doublecortin family of microtubule-associated pro-
teins, DCX, is expressed in chondrocytes (Zhang et al., 2007). 
Within the central nervous system, significant overlap in   
the expression of DCAMKL1 and DCX results in a func-
tional redundancy that masks specific phenotypes in the cen-
tral nervous system that are only observed in Dcamkl1/Dcx 
compound mutant mice (Deuel et al., 2006; Koizumi et al., 
2006; Shu et al., 2006). It is possible that the analysis of mice 
deficient in both Dcamkl1 and Dcx may reveal additional 
skeletal phenotypes, further expanding the functions of the 
microtubule-associated proteins to cell populations outside of 
the osteoblast.
MATERIALS AND METHODS
Mouse mutants. Compound Dcamkl1/Runx2 mutant mice were generated 
using the previously described strains of Dcamkl1/ mice and Runx2+/ mice 
(Mundlos et al., 1997; Otto et al., 1997; Deuel et al., 2006). Animals were 
maintained in accordance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals and were handled according to protocols 
approved by the institution’s subcommittee on animal care (IACUC).
shRNA screen. For the in vitro osteoblast differentiation screen, hMSCs 
(Lonza) were maintained and expanded according to the manufacturer’s in-
structions. For the entire primary and secondary screen, we used hMSCs from 
the same lot and passage to minimize variability. MSCs were seeded at a spe-
cific density in Optilux 96-well plates (BD) in MSC growth media (MSGM) 
and rested overnight. Each well was infected with an individual lentiviral 
clone that expresses a specific and unique shRNA along with a puromycin 
resistance gene. In addition to the 8,000 hairpins corresponding to 1,500 
genes, the screen also included a control 96-well plate that consisted of 90 
individual shRNAs directed against GFP, RFP, luciferase, or -galactosidase. 
Cells that had been successfully infected with the lentiviral clone were selected 
after puromycin treatment and cultured for an additional 4 d. Osteoblast dif-
ferentiation was assessed by measuring levels of Alp. Given the variability in 
viral titer and rate of infection, the level of Alp in a given well was normalized 
to cell number as quantified by the Alamar blue assay (Invitrogen). For this 
assay, cells were cultured in media containing Alamar blue for 4 h at 37°C. 
Plates were read on a fluorometer at 570 nm. Media containing Alamar blue 
was removed, and cells were washed once with sterile PBS. Cells were then 
incubated with 6.5 mM Na2CO3, 18.5 mM NaHCO3, 2 mM MgCl2, and 
Alp substrate (Sigma-Aldrich) for 1 h at room temperature. After the incubation 
period, the plate was read with a luminometer (Thermo Fisher Scientific) at 
405 nm. The Alp data were plotted versus the Alamar blue data to generate an 
XY scatter plot (Fig. 1 C), and a second-order polynomial was used to describe 
a best-fit line for the XY scatter plot. From this best fit line, a predicted Alp 
value is generated for each individual Alamar blue reading. An API, gener-
ated by dividing the actual Alp level by the expected Alp level and then multi-
plying by 100 [API = (actual AP/expected AP) × 100)], was assigned to each 
sample. A mean API and standard deviation were then generated for the entire 
population. A list of candidates was identified in the primary screen based on 
the API of known genes that regulate MSC differentiation. We further vali-
dated these candidates by rescreening the 750 shRNAs corresponding to 
the 150 target genes that were identified by the primary screen. To decrease 
the possibility of false positives, candidates that passed the second screen were 
further validated in MSCs derived from two additional donors.JEM Vol. 210, No. 9 
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